Consideration of an association between performance status and ramucirumab efficacy

Ann Oncol. 2017 Apr 1;28(4):902-903. doi: 10.1093/annonc/mdw688.

Authors

H H Yoon¹, J C Bendell², Z A Wainberg³

Affiliations

¹ Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
² GI Cancer Research Program, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA.
³ Division of Hematology Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

PMID: 28203696
DOI: 10.1093/annonc/mdw688

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal*
Antibodies, Monoclonal, Humanized
Disease-Free Survival
Humans
Ramucirumab

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized